Raquel Lima
Name: Raquel Lima
E-mail: rlima@ipatimup.pt
Extension: 
225570700
Academic Degree: PhD


Raquel Lima
Raquel Lima
Member of
Research Technician of Cancer Signalling & Metabolism


Short CV

Highlights

Supervisor of
Ana Chantre, Master Student (theoretical phase)
MSc student
Bárbara Alves, Master Student (theoretical phase)
MSc student

PI (running)

PI (closed)
First Author
 
C
IF
1. Lima RT, Sousa D, Paiva AM, Palmeira A, Barbosa J, Pedro M, Pinto MM, Sousa E, Vasconcelos MH
Modulation of Autophagy by a Thioxanthone Decreases the Viability of Melanoma Cells. Molecules (Basel, Switzerland) 21: 1343, 2016. [Article] 
 
2. Lima RT, Barron GA, Grabowska JA, Bermano G, Kaur S, Roy N, Helena Vasconcelos M, Lin PK
 PMID: 23092269.
 
3. Lima RT, Seca H, Palmeira A, Fernandes MX, Castro F, Correia-da-Silva M, Nascimento MS, Sousa E, Pinto M, Vasconcelos MH
 doi: 10.1111/cbdd.12109 PMID: 23350710.
 
4. Lima Raquel T., Nascimento M . S. José, Vasconcelos M. Helena
EBV-associated cancers: Strategies for targeting the virus Microbial pathogens and strategies for combating them: science, technology and education 3: 1608-1618, 2013. [] 
.
 
5. Lima RT, Seca H, Brás S, Nascimento MS, Vasconcelos MH
 doi: 10.1159/000323627 PMID: 21540588.
 
6. Lima RT, Seca H, Soares P, Nascimento MS, Vasconcelos MH
EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide. Journal of cellular biochemistry 112: 200-10, 2011. [Article] 
 doi: 10.1002/jcb.22920 PMID: 21069730.
 
.
 
Chemosensitization effects of XIAP downregulation in K562 leukemia cells. Journal of chemotherapy (Florence, Italy) 18: 98-102, 2006. [Article] 
 PMID: 16572900.
 
 
Senior Author
 
C
IF
1. Príncipe C, Dionísio de Sousa IJ, Prazeres H, Soares P, Lima RT
LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals (Basel, Switzerland) 14: ., 2021. [Review] 
 doi: 10.3390/ph14090836 PMID: 34577535.
 
2. Dionísio de Sousa IJ, Cunha AI, Saraiva IA, Portugal RV, Gimba ERP, Guimarães M, Prazeres H, Lopes JM, Soares P, Lima RT
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer. Pathobiology : journal of immunopathology, molecular and cellular biology 88: 400-411, 2021. [Article] 
 doi: 10.1159/000517372 PMID: 34689147.
 
3. Bizarro A, Ferreira IC, Sokovic M, van Griensven LJ, Sousa D, Vasconcelos MH, Lima RT
 
Send Email
From
To
Subject